Numerous case reports of Guillain-Barre syndrome paralysis after Covid-19 vaccine have prompted scientists to warn that "all physicians" should be "vigilant in recognizing Guillain-Barré syndrome in patients who have received the AstraZeneca vaccine... our observations suggest that this clinically distinct [Guillain-Barré syndrome] variant is more severe than usual and may require mechanical ventilation."
In the U.K., scientists flagged "bifacial weakness and normal facial sensation in four men between 11 and 22 days after their first doses of the Astra-Zeneca vaccine."
The AstraZeneca vaccine is not being given in the U.S.
A case of Guillain-Barre has also been identified in a patient who got the Pfizer vaccine.
In India, there are reports of seven severe cases of Guillain-Barré syndrome 10 to 14 days after the first dose of AstraZeneca's vaccine.
Six were women, all had facial paralysis, "all progressed to quadriplegia, and six required respiratory support. Patients' ages ranged from 43 to 70. Four developed other cranial neuropathies, including abducens palsy and trigeminal sensory nerve involvement."
Guillain-Barre syndrome has been reported after other vaccinations. The cause is believed to be damage to the immune system. The disorder can be extremely serious and can lead to total paralysis with dependence on artificial respiration. Even those who recover may have serious muscle wasting and may have to slowly teach the body to relearn most every normal task, such as walking. One in 20 cases is fatal.
Other scientists say there's no evidence that the Guillain-Barre cases are anything other than coincidence, and that they might have occurred in the patients even if they had not been vaccinated.